Clinical Profile and Visual Outcomes after Treatment in Patients with Dysthyroid Optic Neuropathy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To report the clinical data and visual outcomes after treatment of patients with dysthyroid optic neuropathy (DON). Methods: We retrospectively reviewed the medical records and orbital images of 40 patients (65 eyes) with DON and analyzed the visual outcomes after treatment with intravenous steroids pulse therapy, radiotherapy and orbital decompression. Results: The study included 21 men and 19 women, with 10 (25%) being diabetic patients. Visual field test results revealed defects in 88.7% of DON eyes; afferent pupillary defects in 63.2%; reduced color vision in 78.5%; and abnormal visual evoked potentials in 84%. Orbital imaging showed moderate to severe apical crowding in 95% of the orbits and intracranial fat prolapse in 24.2%. Median best corrected visual acuity improved from 0.4 to 1.0 after one year of treatment (p < 0.001). We noted more improvement in vision with the use of decompressive surgery than with non-surgical methods (p < 0.05). Recurrences occurred in 7 patients who had not received orbital radiotherapy. Conclusions: Visual field defects and apical crowding seen on orbital imaging were the most sensitive indicators for the detection of DON. Treatment with intravenous steroids pulse therapy, radiotherapy and orbital decompression effectively improved visual outcomes in cases of DON.
Abstract
Purpose: To report the clinical data and visual outcomes after treatment of patients with dysthyroid optic neuropathy (DON). Methods: We retrospectively reviewed the medical records and orbital images of 40 patients (65 eyes) with DON and analyzed the visual outcomes after treatment with intravenous steroids pulse therapy, radiotherapy and orbital decompression. Results: The study included 21 men and 19 women, with 10 (25%) being diabetic patients. Visual field test results revealed defects in 88.7% of DON eyes; afferent pupillary defects in 63.2%; reduced color vision in 78.5%; and abnormal visual evoked potentials in 84%. Orbital imaging showed moderate to severe apical crowding in 95% of the orbits and intracranial fat prolapse in 24.2%. Median best corrected visual acuity improved from 0.4 to 1.0 after one year of treatment (p < 0.001). We noted more improvement in vision with the use of decompressive surgery than with non-surgical methods (p < 0.05). Recurrences occurred in 7 patients who had not received orbital radiotherapy. Conclusions: Visual field defects and apical crowding seen on orbital imaging were the most sensitive indicators for the detection of DON. Treatment with intravenous steroids pulse therapy, radiotherapy and orbital decompression effectively improved visual outcomes in cases of DON.
참고문헌 (34)
- Lucarelli MJ, "Management of thyroid optic neuropathy", Int Ophthalmol Clin, 36, pp.179~193 (1996)
- Rootman J, "Diseases of the orbit: a multidisciplinaryapproach. 2nd ed", pp.182~196 (2003), Lippincott Williams &Wilkins
- Neigel JM, "Dysthyroid opticneuropathy: the crowded orbital apex syndrome", Ophthalmology, 95, pp.1515~1521 (1988)
- Soares-Welch CV, "Opticneuropathy of Graves disease: results of transantral orbitaldecompression and long-term follow-up in 215 patie", AmJ Ophthalmol, 136, pp.433~441 (2003)
- Trobe JD, "Dysthyroid optic neuropathy:clinical profile and rationale for management", ArchOphthalmol, 96, pp.1199~1209 (1978)
- Kennerdell JS, "Apical opticnerve compression of dysthyroid optic neuropathy oncomputed tomography", Arch Ophthalmol, 99, pp.807~809 (1981)
- Giaconi JA, "CT scan evidence ofdysthyroid optic neuropathy", Ophthal Plast Reconstr Surg, 18, pp.177~182 (2002)
- Day RM, "Optic nerve involvement associatedwith thyroid dysfunction", Arch Ophthalmol, 67, pp.289~297 (1962)
- Chang EL, "Transcaruncular orbitaldecompression for management of compressive opticneuropathy in thyroid-related orbitopathy", Plast ReconstrSurg, 112, pp.739~747 (2003)
- Kazim M, "Insights into the pathogenesisof thyroid-associated orbitopathy: evolving rationalefor therapy", Arch Ophthalmol, 120, pp.380~386 (2002)
- Hedges TR Jr, "Visual field defects in exophthalmosassociated with thyroid disease", AMA Arch Ophthalmol, 54, pp.885~892 (1955)
- Henderson JW, "Optic neuropathy of exophthalmic goiter(Graves’ disease)", AMA Arch Ophthalmol, 59, pp.471~480 (1958)
- Guy JR, "Methylprednisolonepulse therapy in severe dysthyroid optic neuropathy", Ophthalmology, 96, pp.1048~1052 (1989)
- Marcocci C, "Comparisonof the effectiveness and tolerability of intravenous or oralglucocorticoids associated with orbital radiotherapy in themanagement of severe Graves’ ophthalmopathy: results ofa prospective, single-blind, randomized study", J Clin EndocrinolMetab, 86, pp.3562~3567 (2001)
- Kazim M, "Treatment of acute Gravesorbitopathy", Ophthalmology, 98, pp.1443~1448 (1991)
- Hurbli T, "Radiation therapy forthyroid eye diseases", Am J Ophthalmol, 99, pp.633~637 (1985)
- Mourits MP, "Radiotherapy for Graves’ orbitopathy: randomised placebocontrolledstudy", Lancet, 355, pp.1505~1509 (2000)
- Gorman CA, "A prospective,randomized, double-blind, placebo-controlled study oforbital radiotherapy for Graves’ ophthalmopathy", Ophthalmology, 108, pp.1523~1534 (2001)
- Boulos PR, "Thyroid-associated orbitopathy: aclinicopathologic and therapeutic review", Curr Opin Ophthalmol, 15, pp.389~400 (2004)
- McKeag D, "Clinical featuresof dysthyroid optic neuropathy: a European Group onGraves’ Orbitopathy (EUGOGO) survey", Br J Ophthalmol, 91, pp.455~458 (2007)
- Nugent RA, "Graves orbitopathy:correlation of CT and clinical findings", Radiology, 177, pp.675~682 (1990)
- Barrett L, "Optic nervedysf unction in thyroid eye disease: CT", Radiology, 167, pp.503~507 (1988)
- Birchall D, "Gravesophthalmopathy: intracranial fat prolapse on CT imagesas an indicator of optic nerve compression", Radiology, 200, pp.123~127 (1996)
- Durairaj VD, "Clinical features andtreatment of graves ophthalmopathy in pediatric patients", Ophthal Plast Reconstr Surg, 22, pp.7~12 (2006)
- Young LA, "Dysthyroid ophthalmopathy in children", J PediatrOphthalmol Strabismus, 16, pp.105~107 (1979)
- Uretsky SH, "Graves’ ophthalmopathyin childhood and adolescence", Arch Ophthalmol, 98, pp.1963~1964 (1980)
- Kalmann R, "Diabetes mellitus: a risk factorin patients with Graves’ orbitopathy", Br J Ophthalmol, 83, pp.463~465 (1999)
- Day RM, "Corticosteroids in the treatment ofoptic nerve involvement associated with thyroid dysfunction", Trans Am Ophthalmol Soc, 65, pp.41~51 (1967)
- Anderson RL, "Dysthyroidoptic neuropathy without extraocular muscle involvement", Ophthalmic Surg, 20, pp.568~574 (1989)
- Mourits M, "Methylprednisolonepulse therapy for patients with dysthyroid optic neuropathy", Orbit, 20, pp.275~280 (2001)
- Bartalena L, "Orbital cobaltirradiation combined with systemic corticosteroids forGraves’ ophthalmopathy: comparison with systemic corticosteroidsalone", J Clin Endocrinol Metab, 56, pp.1139~1144 (1983)
- Marcocci C, "Orbital radiotherapycombined with high dose systemic glucocorticoidsfor Graves’ ophthalmopathy is more effective than radiotherapyalone: results of a prospective randomized study", JEndocrinol Invest, 14, pp.853~860 (1991)
- Carter KD, "Longtermefficacy of orbital decompression for compressiveoptic neuropathy of Graves’ eye disease", Ophthalmology, 98, pp.1435~1442 (1991)
- Liao SL, "Transcaruncular orbital decompression:an alternate procedure for Graves ophthalmopathywith compressive optic neuropathy", Am J Ophthalmol, 141, pp.810~818 (2006)